AbbVie News Center - News
WEBAbbVie News Center - News. Latest news. September 24, 2024. Empowering Women Entrepreneurs: 2024 BOTOX® (onabotulinumtoxinA) Cosmetic Grant Recipients Kick Off Crowdfunding Campaigns. September 20, 2024. AbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE®) for …
AbbVie to Acquire ImmunoGen, including its Flagship Cancer ... - News
WEBNov 30, 2023 · AbbVie will acquire all outstanding ImmunoGen common stock for $31.26 per share in cash. The proposed transaction is subject to customary closing conditions, including receipt of regulatory approvals and approval by ImmunoGen stockholders. The proposed transaction is expected to be accretive to diluted earnings per share (EPS) beginning in 2027.
AbbVie Inc. (ABBV) Latest Stock News & Headlines - Yahoo Finance
WEBGet the latest AbbVie Inc. (ABBV) stock news and headlines to help you in your trading and investing decisions.
AbbVie Says Pivotal Trial For Parkinson's Candidate Meets Its …
WEB20 hours ago · On Thursday, AbbVie Inc (NYSE: ABBV) released topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson’s disease. Tavapadon is an investigational...
AbbVie Inc. (ABBV) Stock Price, News, Quote & History - Yahoo Finance
WEBFind the latest AbbVie Inc. (ABBV) stock quote, history, news and other vital information to help you with your stock trading and investing.
AbbVie to Acquire Cerevel Therapeutics in Transformative ... - News
WEBDec 6, 2023 · NORTH CHICAGO, Ill. and CAMBRIDGE, Mass., Dec. 6, 2023 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) today announced a definitive agreement under which AbbVie will acquire Cerevel Therapeutics and its robust neuroscience pipeline of multiple clinical-stage and preclinical candidates with potential across ...
AbbVie Inc (ABBV) Stock Price & News - Google Finance
WEBGet the latest AbbVie Inc (ABBV) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
AbbVie raises 2027 sales forecast for new immunology drugs to …
WEBFeb 2, 2024 · AbbVie on Friday raised its 2027 forecast for sales of its immunology drugs Skyrizi and Rinvoq to $27 billion, up $6 billion from its previous prediction.
AbbVie's Parkinson's Disease drug meets main goal in late-stage …
WEB23 hours ago · AbbVie said on Thursday its drug met the main goal in a late-stage trial in patients with early Parkinson's disease.
AbbVie: Upadacitinib Phase 3 Trials' Post-hoc Analysis Show
WEB1 day ago · (RTTNews) - Drug maker AbbVie (ABBV) announced Wednesday positive results from a new post-hoc analysis of Phase 3 Studies, demonstrating efficacy of RINVOQ (upadacitinib) in moderate-to-severe...
Skip to content